|

Mavacamten Clinical Trials

9 actively recruiting trials across 4 locations

No change since May 2026

Also known as: Camzyos

Top Sponsors

  • Bristol-Myers Squibb8
  • Michael Ayers1

Indications

  • Heart Disease9
  • Obstructive Hypertrophic Cardiomyopathy4
  • Obstructive Hypertrophic Cardiomyopathy (oHCM)2
  • Hypertrophic Cardiomyopathy2
  • Breastfeeding1

Other5 trials

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Anchorage, Alaska1 trial

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Alaska Heart Institute

Boston, Massachusetts1 trial

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Analysis Group Inc.

Wilmington, North Carolina1 trial

Mavacamten Pregnancy Surveillance Program

The Mavacamten Pregnancy Surveillance Program, PPD Inc

Charlottesville, Virginia1 trial

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

University of Virginia

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.